Definium Therapeutics Inc. shares soared 50% Monday after late-stage trial data showed “groundbreaking” results in the psychedelic drug developer’s experimental treatment for major depressive disorders.
Earnings Bloomberg Jun 22, 2026
Psychedelic Drugmaker Definium Surges on Depression Drug Success
Definium Therapeutics Inc. shares soared 50% Monday after late-stage trial data showed “groundbreaking” results in the psychedelic drug developer’s experimental treatment for major depressive disorders.
